HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Roy Fleischmann Selected Research

Tuberculosis (Tuberculoses)

1/2022Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
3/2015Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
1/2014Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial.
8/2013Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
8/2004Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Roy Fleischmann Research Topics

Disease

125Rheumatoid Arthritis
03/2024 - 01/2002
26Infections
03/2024 - 01/2002
24Pain (Aches)
10/2022 - 03/2002
16Psoriatic Arthritis
03/2024 - 01/2002
13Fatigue
04/2022 - 08/2004
12Herpes Zoster
03/2024 - 06/2014
12Necrosis
01/2023 - 01/2002
10Neoplasms (Cancer)
01/2024 - 01/2004
10Chronic Disease (Chronic Diseases)
04/2022 - 03/2008
7Ankylosing Spondylitis
11/2020 - 11/2003
7Arthritis (Polyarthritis)
09/2020 - 07/2010
5Psoriasis (Pustulosis Palmaris et Plantaris)
03/2024 - 01/2017
5Inflammation (Inflammations)
10/2022 - 01/2006
5Osteoarthritis
04/2022 - 10/2002
5Tuberculosis (Tuberculoses)
01/2022 - 08/2004
5Opportunistic Infections (Opportunistic Infection)
01/2022 - 08/2004
5Injection Site Reaction
01/2014 - 01/2002
5Rheumatic Diseases (Rheumatism)
05/2010 - 01/2002
4Venous Thromboembolism
03/2024 - 01/2022
3Systemic Lupus Erythematosus (Libman-Sacks Disease)
03/2024 - 05/2016
3Skin Neoplasms (Skin Cancer)
01/2023 - 01/2017
3Disease Progression
08/2020 - 04/2007
3Respiratory Tract Infections (Respiratory Tract Infection)
01/2018 - 11/2003
3Gout
01/2018 - 12/2014
3Lymphoma (Lymphomas)
03/2015 - 05/2006
2Pulmonary Embolism
03/2024 - 01/2018
2Autoimmune Diseases (Autoimmune Disease)
03/2024 - 06/2022
2Cardiovascular Diseases (Cardiovascular Disease)
01/2023 - 01/2022
2Anemia
04/2022 - 05/2012
2Atopic Dermatitis (Atopic Eczema)
11/2020 - 01/2006
2Urinary Tract Infections (Urinary Tract Infection)
01/2018 - 03/2012
2Demyelinating Diseases (Demyelinating Disease)
03/2015 - 08/2004
2Neutropenia
05/2012 - 05/2010
2Hypertension (High Blood Pressure)
05/2012 - 10/2002
2Diarrhea
05/2012 - 03/2012
1Lymphopenia (Lymphocytopenia)
03/2024
1Melanoma (Melanoma, Malignant)
01/2023
1Cutaneous Lupus Erythematosus
01/2022
1COVID-19
12/2021
1Crohn Disease (Crohn's Disease)
11/2020
1Ulcerative Colitis
11/2020

Drug/Important Bio-Agent (IBA)

53Methotrexate (Mexate)FDA LinkGeneric
06/2023 - 01/2002
37tofacitinibIBA
03/2024 - 03/2012
30Adalimumab (Humira)FDA Link
03/2024 - 01/2007
24Antirheumatic Agents (DMARD)IBA
06/2023 - 01/2002
22Janus Kinase InhibitorsIBA
03/2024 - 03/2012
15Tumor Necrosis Factor InhibitorsIBA
03/2024 - 01/2004
12upadacitinibIBA
03/2024 - 01/2018
12ametantrone (HAQ)IBA
04/2022 - 11/2015
11Abatacept (Orencia)FDA Link
06/2023 - 01/2013
10baricitinibIBA
01/2024 - 01/2017
10Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2022 - 01/2002
9sarilumabIBA
10/2023 - 06/2015
8Certolizumab PegolFDA Link
01/2018 - 01/2009
6C-Reactive ProteinIBA
06/2023 - 01/2014
6GlucocorticoidsIBA
06/2020 - 05/2006
6golimumabFDA Link
12/2016 - 07/2010
6Etanercept (Enbrel)FDA Link
11/2014 - 01/2002
6Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link
04/2007 - 01/2002
5Monoclonal AntibodiesIBA
07/2021 - 01/2002
4Janus KinasesIBA
01/2024 - 09/2018
4Adrenocorticotropic Hormone (ACTH)FDA Link
04/2022 - 06/2020
4LipidsIBA
01/2022 - 05/2010
4InterleukinsIBA
07/2021 - 01/2017
4Rituximab (Mabthera)FDA Link
05/2011 - 05/2006
3Anti-Citrullinated Protein AntibodiesIBA
12/2022 - 12/2019
3Phosphotransferases (Kinase)IBA
01/2022 - 05/2010
3Interleukin-1 (Interleukin 1)IBA
01/2018 - 08/2004
3Sulfasalazine (Azulfidine)FDA LinkGeneric
01/2017 - 01/2002
3Infliximab (Remicade)FDA Link
11/2014 - 01/2002
3Interleukin-1 Receptors (Interleukin 1 Receptor)IBA
04/2007 - 01/2002
2Creatine Kinase (Creatine Phosphokinase)IBA
03/2024 - 11/2019
2GLPG0634IBA
01/2024 - 01/2022
2omega-Chloroacetophenone (Mace)IBA
01/2023 - 01/2022
2Biomarkers (Surrogate Marker)IBA
12/2022 - 01/2016
2Janus Kinase 1IBA
01/2022 - 01/2018
2olokizumabIBA
07/2021 - 09/2014
2Interleukin-6 Receptors (Interleukin 6 Receptor)IBA
10/2020 - 01/2020
2Biosimilar PharmaceuticalsIBA
03/2020 - 01/2018
2verinuradIBA
01/2018 - 01/2018
2FebuxostatFDA Link
01/2018 - 12/2014
2Uric Acid (Urate)IBA
01/2018 - 12/2014
2Interleukin-6 (Interleukin 6)IBA
01/2018 - 01/2017
2Hydroxychloroquine (Plaquenil)FDA LinkGeneric
01/2017 - 01/2002
2CreatinineIBA
05/2012 - 05/2010
2Celecoxib (Celebrex)FDA Link
03/2008 - 02/2006
2lumiracoxib (prexige)IBA
03/2008 - 02/2006
2Diclofenac (SR 38)FDA LinkGeneric
10/2002 - 03/2002
2Meloxicam (Mobic)FDA LinkGeneric
10/2002 - 03/2002
1deucravacitinibIBA
03/2024
1Collagen Type I (Type I Collagen)IBA
12/2022
1Proteins (Proteins, Gene)FDA Link
12/2022
1Agammaglobulinaemia Tyrosine KinaseIBA
06/2022
1acetyl 4-aminosalicylic acidIBA
04/2022
1Hemoglobins (Hemoglobin)IBA
04/2022
15-(tetradecyloxy)-2-furancarboxylic acid (TOFA)IBA
11/2020

Therapy/Procedure

38Therapeutics
03/2024 - 01/2004
5Biological Therapy
06/2022 - 01/2009
2Aftercare (After-Treatment)
12/2016 - 11/2015
1Vagus Nerve Stimulation
12/2023